N/A N=88 Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes
Child Behavior Disorders
Primary: App Usage - Parent Set up / Modified an App-based Behavior Plan for the Teen — 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=459 A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
Coronary Artery Disease · Coronary Artery Stenosis · Coronary Disease
Primary: In-segment Late Loss (LL) - Per Subject Analysis — 0.19; 0.13 Millimeter
Phase 3 N=219 Evaluation of N1539 Following Abdominoplasty Surgery
Pain, Post-operative
Primary: Summed Pain Intensity Difference Over the First 24 Hours (SPID24) — -4262.1; -3535.7 units on a scale — p=0.0145
Phase 2 N=253 A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)
Refractory Chronic Cough
Primary: Change From Baseline in Awake Objective Cough Frequency After 12 Weeks of Treatment (Day 84) — -0.40; -0.64; -0.65; -0.86 log coughs/hour — p=0.0971
Phase 2 N=36 Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Stable Angina
Primary: Number of Participants With Elevation of Cardiac Enzyme — 4; 2 Participants
Phase 3 N=1,501 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Primary: Overall Survival — NA; 85.8 months — p=0.90
Phase 3 N=365 Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine
Acute Migraine
Primary: Proportion of Subjects With Pain Freedom — 11; 24; 23; 34 Participants
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
Phase 2 N=45 Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain
Pain
Primary: Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours (NRS SPID-48) After Time 0 — 151.7; 126.4; 149.0 units on a scale
Phase 2 N=41 Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
Stress Disorders, Post-Traumatic · PTSD · Depression
Primary: Impact of Event Scale - Revised (IES-R) — 25.76; 36.32 units on a scale
Phase 2 N=307 Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer
Brain Metastases From Non-small Cell Lung Cancer
Primary: Overall Survival — 185; 209; 209 days — p=0.933
Phase 3 N=780 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Gastric Cancer
Primary: Overall Survival — 17.5; 14.2; 18.1; 14.2 Months — p=0.0565
N/A N=80 A Study of Sternal Closure After Open Heart Surgery: Rigid Versus Wire Closure
Pain
Primary: Intubation Time — 7; 9 hours
N/A N=21 Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee Arthroplasty
Arthroplasties, Hip Replacement · Arthroplasties, Knee Replacement
Primary: Number of Participants With Damage to the Incision and Surrounding Skin — 0; 0; 0; 0 Participants
N/A N=103 Evaluation of WIRION™ EPS in Lower Extremities Arteries
Peripheral Arterial Disease (PAD)
Primary: Freedom From Major Adverse Events (MAE) to 30 Days Post Procedure. — 2 Participants